# Interpace Biosciences, Inc. (IDXG)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/interpace-biosciences-inc/ JSON: https://steadybase.io/company/interpace-biosciences-inc.json Checked Nov 10, 2026. Latest filing read: Oct 30, 2026.

## Company

- Legal name: INTERPACE BIOSCIENCES, INC.
- Ticker: IDXG (OTC)
- SEC CIK: 0001054102
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Parsippany, NJ
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: interpace.com
- Investor relations: https://ir.interpace.com
- LinkedIn: https://www.linkedin.com/company/idxgbiosciences
- Next earnings date: Nov 11, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $38.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/0001493152-26-013646-index.html
- Operating income: $4.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/0001493152-26-013646-index.html
- Net income: $24.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/0001493152-26-013646-index.html
- SG&A: $19.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 30, 2026). Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/0001493152-26-013646-index.html
- Employees: 102 as of Mar 2, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/form10-k.htm
- Shares outstanding: 27,700,904 as of Jul 31, 2026 (10-Q filed Aug 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226036895/0001493152-26-036895-index.html
- Auditor: Eisneramper LLP, Philadelphia, Pennsylvania, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/form10-k.htm

## Business

Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/form10-k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $38.7M | $4.1M | $24.6M | $19.4M |
| Dec 31, 2024 | $46.9M | $8.1M | $6.7M | $21.1M |
| Dec 31, 2023 | $40.0M | $4.0M | $2.0M | $19.6M |
| Dec 31, 2022 | $5.7M | -$3.6M | -$22.0M | $20.1M |
| Dec 31, 2021 | $8.2M | -$6.3M | -$14.9M | $19.9M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/interpace-biosciences-inc.json

## Officers and directors

- Christopher McCarthy, CFO & COO. LinkedIn: https://linkedin.com/in/christopher-mccarthy-cpa-b1a18958. Source: Form 4 filed Aug 20, 2026, https://www.sec.gov/Archives/edgar/data/1054102/000149315226039495/0001493152-26-039495-index.htm
- Thomas W. Burnell, CEO, President & Chairman. Source: Form 4 filed Aug 20, 2026, https://www.sec.gov/Archives/edgar/data/1054102/000149315226039528/0001493152-26-039528-index.htm

## Recent 8-K events

- Oct 15, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/form8-k.htm
- Aug 27, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226040329/form8-k.htm
- Aug 21, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/form8-k.htm
- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/form8-k.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/form8-k.htm
- Apr 1, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/form8-k.htm
- Jan 20, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315226002772/form8-k.htm
- Dec 3, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315225025960/form8-k.htm
- Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000149315225021980/form8-k.htm
- Aug 8, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1054102/000164117225022774/form8-k.htm

## Latest filings

- 8-K filed Oct 15, 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/form8-k.htm
- 10-K filed Mar 30, 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/form10-k.htm
- 10-Q filed Aug 10, 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226036895/form10-q.htm
- DEF 14A filed Jul 7, 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226032369/formdef14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/